Rhythm Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RYTM and other ETFs, options, and stocks.

About RYTM

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. 

CEO
David P. Meeker
CEODavid P. Meeker
Employees
414
Employees414
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
2008
Founded2008
Employees
414
Employees414

RYTM Key Statistics

Market cap
7.29B
Market cap7.29B
Price-Earnings ratio
-36.06
Price-Earnings ratio-36.06
Dividend yield
—
Dividend yield—
Average volume
2.40M
Average volume2.40M
High today
$105.00
High today$105.00
Low today
$105.00
Low today$105.00
Open price
$108.76
Open price$108.76
Volume
177.00
Volume177.00
52 Week high
$122.20
52 Week high$122.20
52 Week low
$74.50
52 Week low$74.50

Stock Snapshot

With a market cap of 7.29B, Rhythm Pharmaceuticals(RYTM) trades at $105.00. The stock has a price-to-earnings ratio of -36.06.

On 2026-11-06, Rhythm Pharmaceuticals(RYTM) stock traded between a low of $105.00 and a high of $105.00. Shares are currently priced at $105.00, which is 0.0% above the low and 0.0% below the high.

Rhythm Pharmaceuticals(RYTM) shares are trading with a volume of 177, against a daily average of 2.4M.

In the last year, Rhythm Pharmaceuticals(RYTM) shares hit a 52-week high of $122.20 and a 52-week low of $74.50.

In the last year, Rhythm Pharmaceuticals(RYTM) shares hit a 52-week high of $122.20 and a 52-week low of $74.50.

RYTM News

The Wall Street Journal 2d
AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals

AstraZeneca CEO Pascal Soriot Michael Nagle / Bloomberg News AstraZeneca AZN 1.92 %increase; up pointing triangle recently made a roughly $10 billion offer to...

AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
Zacks 3d
Rhythm Pharmaceuticals, Inc. Reports Q3 Loss, Beats Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM Quick QuoteRYTM - Free Report) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of...

Rhythm Pharmaceuticals, Inc. Reports Q3 Loss, Beats Revenue Estimates
Simply Wall St 3d
Rhythm Pharmaceuticals Revises LG Chem Deal And Adds $750 Million Loan, Is It Still Cheap?

Why Rhythm Pharmaceuticals Is Back In Focus Rhythm Pharmaceuticals (RYTM) has returned to investor watchlists after amending its global license deal with LG Ch...

Rhythm Pharmaceuticals Revises LG Chem Deal And Adds $750 Million Loan, Is It Still Cheap?

Analyst ratings

90%

of 20 ratings
Buy
90%
Hold
10%
Sell
0%

People also own

Based on the portfolios of people who own RYTM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.